Botox vs Dysport vs Xeomin: Which Neuromodulator Is Right for Your Patients?

botox vs dysport vs xeomin

Every week I talk to medspa owners who stock all three major neuromodulators but cannot clearly explain to their team — or their patients — why they would choose one over another. That gap costs revenue and erodes patient trust. This post is my definitive breakdown of Botox vs Dysport vs Xeomin: onset, duration, cost, conversion units, and the clinical scenarios where each one wins.

I am not going to tell you one is objectively better. What I will tell you is that understanding the differences lets your injectors make smarter choices, your consultants have more confident conversations, and your practice build loyalty with patients who feel genuinely educated rather than sold to.

The Basics: What Are These Products?

All three are FDA-approved botulinum toxin type A neuromodulators. They work by temporarily blocking the nerve signals that cause muscle contractions, reducing the appearance of dynamic wrinkles. The differences come from their formulation, accessory proteins, molecular size, and how they diffuse in tissue.

• Botox (onabotulinumtoxinA) — Allergan/AbbVie; the original and most recognized brand globally
• Dysport (abobotulinumtoxinA) — Galderma; larger molecule, different conversion ratio
• Xeomin (incobotulinumtoxinA) — Merz; “naked” toxin with no accessory proteins

Onset: Which Works Fastest?

Dysport consistently shows the fastest onset in clinical practice. Most patients and injectors report visible results at est. 2–3 days post-injection, compared to est. 3–5 days for Botox and est. 3–4 days for Xeomin. The difference is clinically meaningful for patients with an event coming up in less than a week.

From a marketing standpoint, Dysport’s faster onset is a selling point you can use. “If you have a wedding or reunion in three days, Dysport is my recommendation” is a practical, patient-centered statement that builds confidence and trust.

For patients who have no timing pressure, onset speed is largely irrelevant — and you should not oversell it. Patients who come back and feel their Dysport “wore off faster” because it started faster may not connect those dots themselves, and managing that expectation upfront prevents negative reviews.

Duration: How Long Does Each Last?

Duration is where the clinical picture gets nuanced. All three products are generally described as lasting est. 3–4 months in standard dosing. The real-world differences come from individual metabolism, muscle mass, treatment area, and dosing accuracy.

• Botox: est. 3–4 months average, with some patients extending to 5–6 months after multiple treatments
• Dysport: est. 3–4 months; some practitioners and patients report slightly shorter duration in high-movement areas, though clinical evidence is mixed
• Xeomin: est. 3–4 months; some long-term Botox patients who have developed resistance to accessory proteins report noticeably better duration with Xeomin

Duration claims in patient-facing marketing need to be careful. Promising “up to 6 months” sets an expectation that leads to disappointed patients. Stick to “est. 3–4 months” as your standard language and let overperformance be a pleasant surprise.

Unit Conversion: This Is Where Practices Get Into Trouble

Botox and Xeomin are roughly unit-equivalent: 20 Botox units translates to approximately 20 Xeomin units. Dysport is different — it requires est. 2.5–3 Dysport units to equal 1 Botox unit. This is not because Dysport is weaker; the products are simply measured differently.

Conversion errors are one of the most common billing and clinical mistakes I see in medspa audits. A practice that switches a patient from Botox to Dysport without adjusting the unit count will under-treat and create a dissatisfied patient. When I do a medspa marketing audit, pricing consistency and unit conversion accuracy are two of the first things I check.

When communicating with patients, I recommend against leading with units at all when switching products. Lead with the treatment area and expected outcome. “We’ll treat your forehead and between your brows today — I’ll use Dysport, which works slightly faster, and I’ll adjust the amount to match what you’ve been getting with Botox.”

Cost: What Practices Pay and What Patients Pay

Practice acquisition costs (what you pay the manufacturer or distributor) differ across products, and those differences should factor into your pricing decisions.

• Botox: typically est. $6.50–$8.00 per unit at standard ordering volumes
• Dysport: typically est. $3.00–$4.00 per unit — but remember you need est. 2.5x more units, so the effective cost per Botox-equivalent unit is similar
• Xeomin: typically est. $5.50–$7.00 per unit; Merz often offers competitive pricing to practices willing to commit volume

On the patient side, all three are generally priced the same by practices that use per-unit billing — they adjust the unit count for Dysport to account for the conversion ratio. Practices using per-area flat rates have an even simpler time: the price does not change based on which product is used.

Want to model how your product mix affects your margins? Use my medspa revenue calculator to run your numbers across products.

Best Use Cases: When to Recommend Each

Botox — Best For:

• First-time neuromodulator patients (brand recognition reduces anxiety)
• Patients with very precise placement needs (less diffusion than Dysport)
• Lip flip and perioral lines where tight placement matters
• High-profile or brand-loyal patients who specifically request it

Dysport — Best For:

• Patients with time pressure who need faster onset
• Large muscle groups like the forehead, where broader diffusion can be advantageous
• Patients who feel their Botox “wore off early” — the faster onset may improve perceived duration
• High-volume practices looking for competitive acquisition pricing

Xeomin — Best For:

• Patients who have developed resistance or reduced response to Botox — the lack of accessory proteins eliminates that immune trigger
• Patients with known sensitivities or allergies who may react to accessory proteins
• Practices with longer storage needs — Xeomin’s no-refrigeration-before-reconstitution advantage matters for inventory management
• Patients who are curious about “cleaner” formulations (a real conversation I have with wellness-oriented patients)

The Resistance Conversation

A small percentage of long-term Botox patients develop neutralizing antibodies to the accessory proteins in onabotulinumtoxinA. They notice progressively shorter duration or reduced efficacy over time. These patients are excellent candidates for Xeomin, and if your practice does not proactively identify and address this pattern, those patients will eventually seek answers elsewhere.

Building a protocol to flag patients who report “wearing off early” and offering a Xeomin trial is a smart retention play. I have seen practices recover these patients completely with a single Xeomin cycle, and the loyalty that creates is significant.

Marketing Each Product to Your Patient Base

You do not need to build separate campaigns for each neuromodulator. What you do need is a consultation framework that positions your injectors as knowledgeable enough to customize — and that customization is itself a competitive advantage.

Practices that say “we use whatever is best for you” and can back that up with a coherent explanation outperform practices that say “we use Botox” as if that ends the conversation. That expertise positioning attracts better patients and supports premium pricing.

If you want to build a consultation script that incorporates this kind of product differentiation, browse my medspa marketing resources for frameworks you can adapt immediately.

Staff Training on Neuromodulator Differences

Your front desk and patient coordinators do not need to know the molecular biology. What they need to know:

• All three are safe, FDA-approved, and effective
• Dysport works slightly faster — good for events
• Xeomin is a good option if patients have had reduced results with Botox
• Price is the same regardless of which product the injector uses
• The injector will make the final recommendation based on the patient’s history and goals

That five-point brief is enough for your team to handle 95% of patient questions without escalating to the injector. Train it, role-play it, and you will see smoother consultations and fewer pricing objections tied to product confusion.

If you want help building out your team’s consultation playbook, book a call with me and we can map out a training plan specific to your practice.